An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib

BACKGROUNDS/AIMS: Vitamin K may plays a role in controlling hepatocellular carcinoma (HCC) cell growth. In this study, we intended to present 5-year experience of 72 patients receiving oral vitamin K with or without sorafenib. Its end-point was to evaluate the safety of combination therapy using sor...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Dong-Hwan, Hwang, Shin, Song, Gi-Won, Ryoo, Baek-Yeol, Kim, Nayoung, Tak, Eunyoung, Hong, Hea-Nam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Hepato-Biliary-Pancreatic Surgery 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494089/
https://www.ncbi.nlm.nih.gov/pubmed/26155269
http://dx.doi.org/10.14701/kjhbps.2015.19.1.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494089/
https://www.ncbi.nlm.nih.gov/pubmed/26155269
http://dx.doi.org/10.14701/kjhbps.2015.19.1.1

Ejemplares similares